Please login to the form below

Not currently logged in


This page shows the latest RRMS news and features for those working in and with pharma, biotech and healthcare.

Novartis files for approval of MS drug in EU, US

Novartis files for approval of MS drug in EU, US

Around a quarter of patients with RRMS go onto develop SPMS within 10 years of their initial diagnosis. ... That’s the same mechanism as $3bn-a-year product Gilenya, which is approved to treat RRMS but didn’t hit the mark in SPMS trials.

Latest news

More from news
Approximately 8 fully matching, plus 29 partially matching documents found.

Latest from PMHub

  • It's time to change the conversation

    Take Multiple Sclerosis (MS) for example. MS has four different disease manifestations: Relapsing Remitting (RRMS), Secondary Progressive (SPMS), Primary Progressive (PPMS) and Progressive Relapsing (PRMS). ... Today however, given the research and the

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...